AAP
ABOS icon

Arax Advisory Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

Arax Advisory Partners’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61 Hold
26
– – ﹤0.01% 3648
2025
Q4 		$55 Hold
26
– – ﹤0.01% 3906
2025
Q3 		$44 Buy
+26
New +$36 ﹤0.01% 3540

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Arax Advisory Partners's ABOS Position: Q1 2026 in Review

Arax Advisory Partners held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 26 shares worth $61. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

Arax Advisory Partners first reported a position in ABOS in Q3 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Arax Advisory Partners held 26 shares of Acumen Pharmaceuticals worth $61 as of Q1 2026.
  • Arax Advisory Partners left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3648 holding.
  • Arax Advisory Partners first reported a position in Acumen Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.